David M Robinson

Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRASG12C.

Doyle J Cassar, J. Breed, D. Ogg, 2020, Journal of medicinal chemistry.

Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer

A. Rabow, C. Robson, G. Walker, 2012 .

AZD4625 is a Potent and Selective Inhibitor of KRASG12C

A. Chakraborty, S. Cosulich, E. Wigmore, 2022, Molecular cancer therapeutics.

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Rhys D O Jones, A. Rabow, S. Barry, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics AZD 3514 : A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Rhys D O Jones, A. Rabow, S. Barry, 2013 .

Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C.

Doyle J Cassar, Nichola L. Davies, J. Breed, 2022, Journal of medicinal chemistry.

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

M. Garnett, O. Delpuech, Paul D. Smith, 2020, Molecular Cancer Therapeutics.

Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma

S. Ashton, Matthew J. Martin, D. Cross, 2016, Oncotarget.